Tyrosine kinase inhibitor levels matter in treating chronic GVHD

Bone Marrow Transplant. 2019 Jul;54(7):1141-1144. doi: 10.1038/s41409-018-0429-5. Epub 2019 Jan 16.

Lotte van der Wagen^{1

2}, Julie Janssen³, Reinier Raijmakers¹, Eefke Petersen¹, Moniek de Witte¹, Niels de Jong⁴, Mar Bellido⁵, Ellen Meijer⁶, Brigitte Bär⁷, Jaap Jan Boelens^{2

8}, Alwin Huitema^{3

9}, Jürgen Kuball^{10

11}

¹ Department of Hematology, University Medical Center Utrecht, Room number Q05.4.301, PO Box 85500, Utrecht, GA, 3508, The Netherlands.
² Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
³ Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁴ Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
⁵ Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
⁶ Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
⁷ Department of Hematology, Radboud Medical Center, Nijmegen, The Netherlands.
⁸ Department of Pediatrics, Stem Cell Transplant and Cellular Therapies Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁹ Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
¹⁰ Department of Hematology, University Medical Center Utrecht, Room number Q05.4.301, PO Box 85500, Utrecht, GA, 3508, The Netherlands. j.h.e.kuball@umcutrecht.nl.
¹¹ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. j.h.e.kuball@umcutrecht.nl.

No abstract available

Publication types